Inhibikase Therapeutics
Inhibikase Therapeutics
IKT
NASDAQ
2.20
USD
-0.90%
About
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases.
Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate.
The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 31.6K |
| Three Month Average Volume | 527.6K |
| High Low | |
| Fifty-Two Week High | 3.82 USD |
| Fifty-Two Week Low | 0.79 USD |
| Fifty-Two Week High Date | 25 Jan 2024 |
| Fifty-Two Week Low Date | 10 Oct 2023 |
| Price and Volume | |
| Current Price | 1.4 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -0.36% |
| Thirteen Week Relative Price Change | -28.91% |
| Twenty-Six Week Relative Price Change | -40.78% |
| Fifty-Two Week Relative Price Change | -44.41% |
| Year-to-Date Relative Price Change | -6.91% |
| Price Change | |
| One Day Price Change | 0.97% |
| Thirteen Week Price Change | -23.91% |
| Twenty-Six Week Price Change | -34.88% |
| Five Day Price Change | -2.10% |
| Fifty-Two Week Price Change | -30.35% |
| Year-to-Date Price Change | 10.24% |
| Month-to-Date Price Change | -0.71% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.77456 USD |
| Book Value Per Share (Most Recent Quarter) | 0.70628 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.77456 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.70628 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.99239 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.04885 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.01255 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.56807 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.93082 USD |
| Normalized (Last Fiscal Year) | -3.56807 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.56807 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.93082 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.56807 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.93082 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.14217 USD |
| Cash Per Share (Most Recent Quarter) | 1.10031 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.53481 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.89417 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.59662 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -970 |
| Cash Flow Revenue (Trailing Twelve Months) | -20,697 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -23,102.16% |
| Pretax Margin (Last Fiscal Year) | -7,304.75% |
| Pretax Margin (5 Year) | -1,139.14% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -7,712.01% |
| Operating Margin (Trailing Twelve Months) | -23,885.07% |
| Operating Margin (5 Year) | -1,159.14% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -7,304.75% |
| Net Profit Margin (Trailing Twelve Months) | -23,102.16% |
| Net Profit Margin (5 Year) | -1,139.14% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -42.21% |
| Revenue Change (Trailing Twelve Months) | -68.40% |
| Revenue Per Share Growth | -54.99% |
| Revenue Growth (5 Year) | -28.02% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 40.47% |
| EPS Change (Trailing Twelve Months) | 29.73% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -7,940,020 |
| Net Debt (Last Fiscal Year) | -13,252,050 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 40 |
| Price to Sales (Trailing Twelve Months) | 131 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 4 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -18,099,280 |
| Free Cash Flow (Trailing Twelve Months) | -16,468,910 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -96.49% |
| Return on Assets (Trailing Twelve Months) | -117.93% |
| Return on Assets (5 Year) | -66.49% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -118.88% |
| Return on Equity (Trailing Twelve Months) | -149.69% |
| Return on Equity (5 Year) | -86.53% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -117.79% |
| Return on Investment (Trailing Twelve Months) | -148.63% |
| Return on Investment (5 Year) | -85.55% |